Baxter International Inc. (BAX)
Baxter- Reiterating Our Buy Rating After A Promising Q2
BAX's Novum IQ Large Volume Pumps are playing a key role in driving topline progress, whilst the HST division too looks set to benefit from a few tailwinds. BAX's revamped operating model is paying off with strong operating leverage expected this year (14% bottomline growth on 3% topline growth). The current yield is already quite compelling at over 3%, but the sale or spin-off of the Kidney Care Division by Q1-25 could lead to a long overdue dividend hike.
Baxter (BAX) Q2 Earnings Beat Estimates, '24 EPS View Raised
Baxter (BAX) reports better-than-expected second-quarter earnings and sales. Its quarterly results reflect solid demand for a range of its medically essential products.
Baxter International Inc. (BAX) Q2 2024 Earnings Call Transcript
Baxter International Inc. (NYSE:BAX ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Clare Trachtman - Senior Vice President, Chief Investor Relations Officer Joe Almeida - Chairman & Chief Executive Officer Joel Grade - Executive Vice President & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America Securities David Roman - Goldman Sachs Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Danielle Antalffy - UBS Matt Miksic - Barclays Rick Wise - Stifel Pito Chickering - Deutsche Bank Operator Good morning, ladies and gentlemen, and welcome to Baxter International's Second Quarter 2024 Earnings Conference Call. Your lines will remain in a listen-only mode until the question-and-answer segment of today's call.
Compared to Estimates, Baxter (BAX) Q2 Earnings: A Look at Key Metrics
The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Baxter International (BAX) Beats Q2 Earnings and Revenue Estimates
Baxter International (BAX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.55 per share a year ago.
The Zacks Analyst Blog Baxter International, Henry Schein and IDEXX Laboratories
Baxter International, Henry Schein and IDEXX Laboratories are included in this Analyst Blog.
3 Contrarian Stock Picks to Buy Against the Market Consensus
Heightened volatility on Wall Street means contrarian stock picks can be a game-changer for savvy investors. A contrarian investing strategy involves buying overlooked assets with the expectation that they will eventually increase in value.
What's in Store for These 3 MedTech Stocks in Q2 Earnings?
MedTech companies' quarterly results are likely to be strong on a sequential basis. Let's see how BAX, HSIC and IDXX are placed ahead of their earnings releases.
Countdown to Baxter (BAX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Get a deeper insight into the potential performance of Baxter (BAX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Baxter's (BAX) Helion Surgical System Debuts in Thailand
Baxter (BAX) launches the Helion Integrated Surgical System in Thailand, aiming to streamline operating room efficiency and enhance surgical team connectivity with cutting-edge technology.
Baxter: Why Investors Should Take Advantage Of The Low Valuation
Baxter has been a poor performer over the last year. The stock now trades with an extremely low valuation relative to the stock's historical performance. Recently, the company raised guidance, which points to double-digit earnings growth. Analysts seem to believe this growth is sustainable.
Baxter International Stock Downgraded on Margin Concerns
Shares of Baxter International Inc (NYSE:BAX) are down 2.9% at $34.28, after a downgrade from Morgan Stanley to "underweight" from "equal weight," with a price-target cut to $30 from $39.
